Lilly signs $1.3 billion deal with Superluminal to discover obesity medicines using AI
Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases.
More info
